US 11,814,441 B2
Bi-specific antigen-binding polypeptides
Yan Chen, Lexington, MA (US); Richard W. Wagner, Cambridge, MA (US); Keming Zhang, Waltham, MA (US); and Pascale Richalet, Waltham, MA (US)
Assigned to X-BODY, INC., Waltham, MA (US)
Filed by X-BODY, INC., Waltham, MA (US)
Filed on Jan. 22, 2019, as Appl. No. 16/253,691.
Application 16/253,691 is a continuation of application No. 14/664,018, filed on Mar. 20, 2015, granted, now 10,202,462.
Claims priority of provisional application 61/968,437, filed on Mar. 21, 2014.
Prior Publication US 2019/0248918 A1, Aug. 15, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/32 (2006.01); C07K 16/46 (2006.01); C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/32 (2013.01) [C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C07K 16/46 (2013.01); A61K 38/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
 
1. An isolated bi-specific antigen-binding polypeptide comprising an antibody heavy chain comprising a first VH domain that specifically binds to human HER2, wherein the heavy chain is C-terminally linked to a second VH domain that specifically binds to human PDGFRβ, wherein the polypeptide is devoid of antibody light chains, and wherein the VH domain that binds specifically to human HER2 comprises:
a HCDR3 comprising the amino acid sequence set forth as SEQ ID NO: 1,
a HCDR2 comprising the amino acid sequence set forth as SEQ ID NO: 2, and
a HCDR1 comprising the amino acid sequence set forth as SEQ ID NO: 3; or
a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 4,
a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and
a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 6; or
a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 7,
a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 8, and
a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 9; or
a HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 10,
a HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 11, and
a HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12.